Showing results (41-50 of 57) with videos related to
Sort By:
Pageof 6
Haematologica|October 15, 2020
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaborationDeborah M Stephens, Ken Boucher, Elizabeth Kander, et al.Haematologica|March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialPau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2022
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialCatherine Thieblemont, Tycel Phillips, Herve Ghesquieres, et al.British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.Journal for Immunotherapy of Cancer|June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.Blood|January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent LymphomaNathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.Pageof 6